首页> 外文期刊>Platelets >Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing
【24h】

Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing

机译:从韩国人群中经皮冠状动脉介入治疗患者的平均血小板量预测临床结局:比血小板功能测试更简单,更有用的测试的含义

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to determine the associations of the mean platelet volume (MPV) with the development of adverse outcomes after percutaneous coronary intervention (PCI) and platelet reactivity. MPV and platelet function testing were analysed in 208 patients who underwent PCI. The primary endpoint was cardiac death. The secondary endpoint analysed was cardiovascular events (CVE): the composite of myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis (ST). The median MPV level, aspirin reaction unit (ARU), P2Y12 reaction units (PRU) and P2Y12% inhibition (PI%) of clopidogrel were 8.55 (IQR 8.00-9.18) fl, 401.0 (IQR 389.3-442.0) ARU, 222.0 (IQR 169.0-272.3) PRU and 22 (IQR 9-38) %, respectively. We observed that high values of MPV were associated with elevated ARU (r = 0.165, p = 0.017) and decreased PI% (r = -0.167, p = 0.016). There were 10 events of cardiac death, 3 MI (including 1 event of ST), and 8 TVR during a mean of 7.6 months of follow-up. The Kaplan-Meier analysis revealed that the higher MPV group (°8.55 fl, median) had a significantly higher cardiac death rate compared to the lower MPV group (<8.55 fl) (7.7% vs. 1.9%, log-rank: p = 0.035). However, aspirin or clopidogrel resistance (>550 ARU, <40 PI%, respectively) did not predict cardiac death. When the MPV cut-off level was set to 8.55 fl using the receiver operating characteristic curve, the sensitivity was 80% and the specificity was 51.5% for differentiating between the group with cardiac death and the group without cardiac death. This value was more useful in patients with clinical diagnosis of acute coronary syndrome (ACS). Furthermore, ACS patients with an MPV over 8.55 fl had high cardiac death and CVE risk without atorvastatin loading before PCI (Log-Rank = 0.0031, 0.0023, respectively). The results of this study show that MPV was a predictive marker for cardiac death after PCI; its predictive power for cardiac death was more useful in patients with ACS.
机译:这项研究的目的是确定经皮冠状动脉介入治疗(PCI)后平均血小板体积(MPV)与不良结局的发展以及血小板反应性之间的关系。对208例行PCI的患者进行了MPV和血小板功能测试。主要终点是心脏死亡。分析的次要终点是心血管事件(CVE):心肌梗塞(MI),目标血管血运重建(TVR)和支架血栓形成(ST)的复合物。氯吡格雷的MPV中位数,阿司匹林反应单位(ARU),P2Y12反应单位(PRU)和P2Y12%抑制(PI%)为8.55(IQR 8.00-9.18)fl,401.0(IQR 389.3-442.0)ARU,222.0(IQR) 169.0-272.3)PRU和22(IQR 9-38)%。我们观察到高MPV值与ARU升高(r = 0.165,p = 0.017)和PI%降低(r = -0.167,p = 0.016)相关。在平均7.6个月的随访期间,发生了10例心源性死亡,3例MI(包括1例ST)和8例TVR。 Kaplan-Meier分析显示,较高的MPV组(8.55 fl,中位数)与较低的MPV组(<8.55 fl)相比,其心脏死亡率显着较高(7.7%vs. 1.9%,对数秩:p = 0.035)。但是,阿司匹林或氯吡格雷抵抗性(分别> 550 ARU,分别<40 PI%)不能预测心脏死亡。使用接收器工作特征曲线将MPV截止水平设为8.55 fl时,区分心源性死亡组和无心源性死亡组的敏感性为80%,特异性为51.5%。该值在具有急性冠脉综合征(ACS)临床诊断的患者中更有用。此外,MPV值超过8.55 fl的ACS患者在PCI前没有阿托伐他汀负荷的情况下有较高的心源性死亡和CVE风险(分别为Log-Rank = 0.0031、0.0023)。这项研究的结果表明,MPV是PCI后心源性死亡的预测指标。它对心源性死亡的预测能力在ACS患者中更有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号